Phaseline

Targets › SLC7A5

SLC7A5 (Large neutral amino acids transporter small subunit 1): drug programs, companies and trials

5 programs from 5 companies in 5 trials: 3 Phase 1, 2 Phase 4; Oncology; next expected readout Dec 2026.

Forms a heterodimer with SLC3A2 that functions as a sodium-independent transporter for large neutral amino acids. Functions as an obligatory amino acid antiporter, mediating the exchange of amino acids and amino acid-related compounds across the plasma membrane. (UniProt, Q01650)

Open in Phaseline: the race on SLC7A5, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
OHSU Knight Cancer InstituteFluciclovine PET/CT
18F-labeled amino acid PET tracer; uptake via LAT1 (large neutral amino acid transporter 1
SLC7A5Phase 4Prostate CancerDec 2026
VA Greater Los Angeles Healthcare System18F-Fluciclovine PET/CT
Amino acid PET imaging agent targeting amino acid transporters in cancer cells
SLC7A5Phase 4Prostatic NeoplasmsNov 2027
Heron Neutron MedicalF18 FBPA
Radiolabeled phenylalanine analog with uptake facilitated by L-type amino acid transporter
SLC7A5Phase 1Solid TumorDec 2026
Abramson Cancer Center at Penn MedicineFluoroglutamine [18F]F-GLN
18F-labeled glutamine PET imaging agent
SLC7A5Phase 1Breast CancerDec 2026
Brigham and Women's Hospital18F-fluciclovine
Amino acid transporter targeting radiotracer
SLC7A5, SLC7A8Phase 1Advanced Prostate CancerSep 2027

Conditions

Breast Cancer (1) Prostate Cancer (1) Advanced Prostate Cancer (1) Prostatic Neoplasms (1) Solid Tumor (1)

Modalities

small molecule (5)

Companies

Abramson Cancer Center at Penn Medicine (1) OHSU Knight Cancer Institute (1) Brigham and Women's Hospital (1) VA Greater Los Angeles Healthcare System (1) Heron Neutron Medical (1)

Related targets

SLC7A8 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.